Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

NCT06967753 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HIV
HIV-1

Interventions

DRUG: Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)

Sponsor

UBATEC

Collaborators

[object Object]
[object Object]